http://pharmasprings.com/ijcpms/issue/feed 2024-07-22T22:12:49+0530 Editor editorijcpms@pharmasprings.com Open Journal Systems <div> <img style="width: 100%;" src="https://pharmasprings.com/templates/frontend/pages/slideshow/slideshow2.gif" /></div> <p align="justify">International Journal of Clinical Pharmacokinetics and Medical Sciences <em>(IJCPMS)</em> ISSN: 2583-0953 is established in the year 2021 officially sponsored by <em><strong>pharma springs publication</strong></em>. We are pleased to introduce ourselves as the novel imminent, and sovereign online pharmacy &amp; medical information services in India. The foundation aims to serve as a means for updating the scientific knowledge of the international audience in the research field of science so a correlation can be made between these researchers. IJCPMS will be published quarterly per year in March, Jun, September, and December. The journal publishes the work that contributes significantly to further the scientific knowledge in the areas of pharmaceutical, medical &amp; biological sciences. All contributions to the journal are rigorously refereed and are selected based on the quality and originality of the work.</p> http://pharmasprings.com/ijcpms/article/view/637 2024-07-22T21:57:29+0530 Sireesha Bollavaram sireshabollavaram@gmail.com Bee Shahida sireshabollavaram@gmail.com

<p>Tolcopone and Quinapril are anti-hypersensitive drugs and, in combined dosages, are effective in managing hypertension. The RP-HPLC method was developed using OPA and Acetonitrile in 50:50 v/v as Mobile phase and 250*4.6mm, 5µ RP-HPLC column measured with a wavelength of 240nm. The HPLC system was fixed with a flow rate of 1.0ml/min; Both drugs, TOLCO and QUINA, were successfully detected at 2.153 and 3.203 min, respectively. The validation of the method as per ICH Linearity r² lies at 0.999, and Precision, system suitability, and selectivity RSD values are within permissible limits. The accuracy of the process was found to be 99.73 and 99.52 for TOLCO and QUINA, respectively. The LOD 0.72 and 0.3 µl/ml and LOQ 0.84 and 0.13 µl/ml. The robustness and degradation studies show that the selected method is acceptable per the Guidelines.Bottom of Form</p>

2024-07-22T00:00:00+0530 Copyright (c) 2024 International Journal of Clinical Pharmacokinetics and Medical Sciences http://pharmasprings.com/ijcpms/article/view/624 2024-07-05T21:59:37+0530 Venugopalaiah Penabaka pvenupharma@gmail.com Lakshman Adarsh Koppala pvenupharma@gmail.com Malathi Mattempati pvenupharma@gmail.com Harathi Mondi pvenupharma@gmail.com Jayasri Poojitha Pula pvenupharma@gmail.com Firdaus Tabassum Shaik pvenupharma@gmail.com Prapurna Chandra Yadala pvenupharma@gmail.com

<p>The study was undertaken to develop and characterize docetaxel-loaded lyophilized block co-polymeric micelles for cancer therapy treatment. The study demonstrates that micellar size, shape, zeta potential, and other characteristics of lyophilized polymeric micelles are appropriate; furthermore, because of the polymer's encapsulation and capacity to maintain the drug release, significantly reduces toxicity and adverse effects. Block co-polymeric micelles offer improved solubility and a high capacity for drug loading, perhaps enhancing the bioavailability. As per this research, the idea of employing block co-polymeric micelles to enhance the solubility of hydrophobic medications holds excellent promise as an intravenous drug delivery system. While the outcomes are encouraging, the docetaxel-loaded block co-polymeric micelles must be further evaluated for In-Vivo studies to check the targeted drug delivery.Bottom of Form</p>

2024-07-22T00:00:00+0530 Copyright (c) 2024 International Journal of Clinical Pharmacokinetics and Medical Sciences